Search for: "Schering AG"
Results 61 - 80
of 89
Sort by Relevance
|
Sort by Date
28 Sep 2009, 1:08 am
The study was funded with an unrestricted grant from Bayer Schering Pharma AG. [read post]
27 Sep 2009, 12:38 am
Merck, which is set to buy rival Schering-Plough Corp. by the end of the year, won 11 of 16 Vioxx suits at trial before agreeing to settle all claims. [read post]
16 Sep 2009, 1:38 pm
Franz-Josef Renneke -- who is the Site Manager for Bayer HealthCare - Bayer Schering Pharma AG at its manufacturing facility in Bergkamen, Germany. [read post]
11 Sep 2009, 3:00 pm
Prior to Secretary Wells' appointment, she was President of the Schering-Plough Foundation, the philanthropic arm of the Schering Plough Corporation and the Vice-President of Public Affairs at Schering-Plough Corporation. [read post]
26 Aug 2009, 5:14 pm
"); Bayer Schering Pharma AG v. [read post]
26 Aug 2009, 9:20 am
"); Bayer Schering Pharma AG v. [read post]
16 Aug 2009, 2:20 am
" Schering-Plough Corp.'s Marvelon and Cerazette pills, which contain desogestrel, generated $319 million for the Kenilworth, New Jersey-based company in the first quarter, IMS Health data show. [read post]
9 Aug 2009, 9:59 pm
Common Sense, Perhaps, But Whose? [read post]
2 Aug 2009, 8:33 pm
Bayer Schering Pharma AG et al. v. [read post]
25 Jun 2009, 4:29 am
This post is largely about drug and medical device litigation "inside baseball. [read post]
1 May 2009, 8:25 am
SEC Investigating Schering-Plough Trades: The SEC is investigating trading of Schering-Plough shares ahead of the announcement of its merger with Merck & Co., people familiar with the matter said. [read post]
3 Apr 2009, 7:23 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
14 Mar 2009, 5:13 am
This study was funded by Schering-Plough. [read post]
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
Schering-Plough Corp. v. [read post]
23 Jan 2009, 12:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property) Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of… [read post]
19 Sep 2008, 6:00 pm
: (IP finance), United States: An open letter for the General Counsel of the PTO on your San Diego presentation next week: (Hal Wegner), United States: Cocoa genome: breaking intellectual property barriers: (Thomson Reuters Scientific), Vietnam: Patentability of second medical use claims in Vietnam is again questionable: (Trung Truc JSC) Pharma & Biotech - Products Allegra (Fexofenadine) - Canada: Motion for summary judgment of noninfringement dismissed in patent infringement… [read post]
7 Sep 2008, 2:47 pm
For example, let's look at Schering-Plough's "49 Plan," which was an aggressive seven-week sales push to increase Zetia prescriptions across the country. [read post]
3 Jul 2008, 7:26 pm
Regular readers know that we've been keeping two "scorecards" - one for drug preemption, and one for device preemption. [read post]
13 Jun 2008, 3:40 am
, Schering-Plough Corp – Following dispute over trade dress with Schering-Plough, Fruit of the Earth announces plan to change its package design: (IP Law360), US: Quanta and its impact on biotechnology: (Holman’s Biotech IP Blog), US: BIO files amicus brief asking CAFC to cabin in scope of KSR and hold that its obvious to try dicta does not abrogate the Deuel standard: In re Kubin: (Patently-O), US: StemCells gets patent on enriched central nervous system stem… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
